RE: Delighted24 Jul 2023 15:52
Here’s one from the 23rd april
"The US trial sites in New York and Seattle will play a key role, along with other sites in the UK and US, in this multi-centre trial both in the dose escalation phase and in the dose expansion phase which we expect to begin in the second half of the year.
"Dosing the first patient in the US is a key milestone and reflects the continuing excellent progress in the ALS-6000-101 clinical trial and the Therapeutics Division as a whole."
97p🤣🤣🤣